Medicus Pharma Ltd. Common Stock (NASDAQ:MDCX) — Market Cap & Net Worth
Market Cap & Net Worth: Medicus Pharma Ltd. Common Stock (MDCX)
Medicus Pharma Ltd. Common Stock (NASDAQ:MDCX) has a market capitalization of $18.41 Million ($18.41 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25406 globally and #5309 in its home market, demonstrating a 8.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medicus Pharma Ltd. Common Stock's stock price $0.35 by its total outstanding shares 56658164 (56.66 Million). Review Medicus Pharma Ltd. Common Stock balance sheet liabilities to assess the company's total debt and financial obligations.
Medicus Pharma Ltd. Common Stock Market Cap History: 2026 to 2026
Medicus Pharma Ltd. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $19.93 Million to $19.93 Million (0.00% CAGR).
Medicus Pharma Ltd. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medicus Pharma Ltd. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MDCX by Market Capitalization
Companies near Medicus Pharma Ltd. Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to Medicus Pharma Ltd. Common Stock by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #26 globally with a market cap of $564.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1112.00 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #26 | Johnson & Johnson | NYSE:JNJ | $564.26 Billion | $234.20 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $221.23 |
Medicus Pharma Ltd. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Medicus Pharma Ltd. Common Stock's market cap moved from $19.93 Million to $ 19.93 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $19.93 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Medicus Pharma Ltd. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.41 Million USD |
| MoneyControl | $18.41 Million USD |
| MarketWatch | $18.41 Million USD |
| marketcap.company | $18.41 Million USD |
| Reuters | $18.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The com… Read more